ClinicalTrials.gg
WithdrawnNCT05056558Updated Nov 5, 2026

Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19

A Phase 3 interventional study of Baricitinib and Placebo in Covid19, sponsored by Incepta Pharmaceuticals Ltd. Withdrawn at 1 site in Bangladesh. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Incepta Pharmaceuticals Ltd · Phase 3, Interventional, and Treatment

Why this study was withdrawn
The study was planned during COVID-19 outbreak to assess Baricitinib in Patients With Moderate and Severe COVID-19. The study could not be started due to many obstacle which was raised because of Pandemic. The study is no more relevant.
Updated Nov 5, 2026Now WithdrawnStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing baricitinib in COVID-19 — 3 open to participants now, 4 under way, 3 of them phase 3. baricitinib · COVID-19.

Enrollment
18th of 20
0 · median 184
Started
2020
with 12 others
Phase 3
9 of 20
3 open now
Registered
16th of 20
by date
Lead sponsor
1 of 20
Incepta Pharmaceuticals Ltd

Among the 20 studies testing baricitinib in COVID-19, this one is the 18th largest by enrollment, is one of 13 that started in 2020, is one of 9 in phase 3, and was the 16th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 20 studies testing baricitinib in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing baricitinib in COVID-19, or all of them as a file.
02

Study summary

This is multicenter clinical trial to evaluate efficacy and safety of Baricitinib in treatment for COVID-19. This trial will compare Baricitinib, a drug recommended for Rheumatoid Arthritis, against standard of care, to assess its relative effectiveness against COVID-19. By enrolling patients in multiple centers, this trial aims to recruit more patients to evaluate whether this drug slow disease progression or improve survival. Currently no effective therapeutics treatment or vaccine is available in the world for this highly transmissible respiratory borne infection, Covid-19. A number of drug trials are ongoing to measure the efficacy of the drug against the virus. Bangladesh as a resource limited country with limitation to provided health care services to the huge number of Covid-19 patients who will need hospitalization will be benefited from this study. There is no physical, psychological, social, legal risk in this study. The trial therapeutic will be approved form the Directorate of drug Administration (DGDA), Bangladesh.

03

Conditions studied

  • Covid19

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • SARS-Co-V2 positivity to the nasal-swab by reverse-transcriptase-polymerase chain- reaction (RT-PCR) assay tested by the local diagnostic laboratory
  • Age >18 years
  • Presence of any symptoms suggestive of COVID-19, such as such as fever, fatigue, cough (with or without sputum production), shortness of breath, sore throat, nasal congestion, anorexia, malaise, or headache. Rarely, patients may also present with diarrhea, nausea, and vomiting
  • Presence of radiological findings of pneumonia assessed by chest radiograph, computed tomography
  • Moderate and severe COVID-19 as per previous definition national guideline/WHO
  • Give informed written consent

Exclusion criteria

Exclusion Criteria:

  • Absolute lymphocyte count \<500/mm3 and of \<1000/mm3 and 8gm/dl or less
  • Severe hepatic or renal impairment
  • within 3 months prior to first dose of the drug
  • Pregnancy
  • Lactation
  • Current or history of malignancies over the previous 5 years and/or history of malignancies in first degree relatives
  • Transaminases values 5-fold higher than the upper normal limit
  • Proven evidence of concomitant bacterial infections
  • Clinical evidences suggestive of pulmonary tuberculosis, or past history and/or history of contact with TB patient
  • Known to Baricitinib
  • Those who have received Tocilizumab previously
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Baricitinib

    Continued SOC together with oral 4 mg Baricitinib from day 1 to day 14

    Drug: Baricitinib

  • Placebo comparator
    Placebo

    Continued SOC according as mentioned in operational definition in the protocol

    Drug: Placebo

Interventions

  • Continued standard of care (SOC) together with oral 4 mg Baricitinib tablet from day 1 to day 14

    Also known as: Baricent

  • DrugPlacebo

    Continued standard of care (SOC) together with oral placebo tablet from day 1 to day 14

    Also known as: Given Orally

06

What researchers measure

Primary outcomes

  1. Clinical status assessed by a 7-point ordinal scale on Day 14

    The ordinal scale is an assessment of the clinical status at a given study day. Each day, the worst(ie, lowest ordinal) score from the previous day will be recorded, ie, on Day 3, the lowest ordinal score from Day 2 is obtained and recorded for Day 2. The scale is as follows: 1. Death 2. Hospitalized, on invasive mechanical ventilation or ECMO 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices 4. Hospitalized, requiring low flow supplemental oxygen 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than per protocol Baricitinib administration) 7. Not hospitalized

    Time frame: Day 1 to Day 14

Secondary outcomes

  1. The proportion of participants with treatment emergent adverse events

    Time frame: Day 1 to Day 28

Other outcomes

  1. Time to clinical improvement (days): clinical improvement is defined as a ≥ 2-point improvement in clinical status (7-point ordinal scale) from Day 1

    Time frame: Day 1 to Day 28

  2. Time to ≥ 1-point improvement (days) from baseline clinical status

    Time frame: Day 1 to Day 28

  3. Time to recovery: defined as an improvement in clinical status from a baseline score of 2 through 5 to a score of 6 or 7, or an improvement from a baseline score of 6 to a score of 7

    Time frame: Day 1 to Day 28

  4. Duration of oxygen therapy (days)

    Time frame: Day 1 to Day 28

  5. Proportion of patients with shift in oxygen support status from baseline

    Time frame: Day 1 to Day 28

  6. Duration of hospitalization (days)

    Time frame: Day 1 to Day 28

  7. Number of patients with all-cause mortality at Day 28

    Time frame: Day 1 to Day 28

07

Study locations

1 site
  • Dhaka Medical College, Mugda Medical College, Kuwait Bangladesh Friendship Government Hospital
    Dhaka, Bangladesh
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jul 2020; primary completion for Jul 2025, 60 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Oct 2021 → Jul 2020, primary completion Apr 2022 → Jul 2025 and completion Sep 2022 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2021
First posted
Sep 24, 2021
StartEst.
Jul 30, 2020was Oct 2021
Primary completionEst.
Jul 30, 2025was Apr 2022
CompletionEst.
Apr 12, 2026was Sep 2022
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Withdrawn The study was planned during COVID-19 outbreak to assess Baricitinib in Patients With Moderate and Severe COVID-19. The study could not be started due to many obstacle which was raised because of Pandemic. The study is no more relevant.
changed Nov 5, 2026
Start date
Oct 2021→Jul 30, 2020
Nov 5, 2026
Primary completion
Apr 2022→Jul 30, 2025
Nov 5, 2026
Study completion
Sep 2022→Apr 12, 2026
Nov 5, 2026
Enrollment
480 (estimated)→0 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Status unknown→Withdrawn
    Why stopped The study was planned during COVID-19 outbreak to assess Baricitinib in Patients With Moderate and Severe COVID-19. The study could not be started due to many obstacle which was raised because of Pandemic. The study is no more relevant.
    Start date Oct 2021→Jul 30, 2020
    Primary completion Apr 2022→Jul 30, 2025
    Study completion Sep 2022→Apr 12, 2026
    Enrollment 480 (estimated)→0 (actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05056558
Lead sponsor
Incepta Pharmaceuticals Ltd
Responsible party
Sponsor
First posted
Sep 24, 2021
Start date
Jul 30, 2020 (estimated)
Primary completion
Jul 30, 2025 (estimated)
Completion
Apr 12, 2026 (estimated)
Last update
Nov 5, 2026

Study contacts

Md. Titu Miah, MBBS, FCPS
principal investigator · Dhaka Medical College
Md. Mujibur Rahman, MBBS, MD
principal investigator · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion